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Therapeutic Value of Lymph Node Dissection Along the Superior Mesenteric Vein 
and the Posterior Surface of the Pancreatic Head in Gastric Cancer Located in the 
Lower Third of the Stomach
Hiroaki Saito, Yusuke Kono, Yuki Murakami, Yuji Shishido, Hirohiko Kuroda, Tomoyuki Matsunaga, Yoji 
Fukumoto, Tomohiro Osaki, Keigo Ashida and Yoshiyuki Fujiwara
Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8504, 
Japan
ABSTRACT
Background    Therapeutic value of lymph node dis-
section along the superior mesenteric vein (14v) and the 
posterior surface of the pancreatic head (13) remains 
unclear in gastric cancer patients.
Methods    We reviewed 355 patients with advanced 
gastric cancer in the lower third of the stomach who had 
undergone gastrectomy at our hospital.
Results    The frequency of lymph node (LN) metastasis 
was 10.2% and 7.4% in stations 13 and 14v, respectively. 
The frequency of station 13 metastasis was 26.8% for 
T3/T4 tumors with group 2 LNs metastasis and 1.4% for 
all other tumors. The frequency of station 14v metastasis 
was 22.2% for T3/T4 tumors with group 2 LNs metasta-
sis and 1.8% for all other tumors. The therapeutic values 
for dissecting LN stations 13 and 14v were 1.9 and 0.9, 
respectively, similar to the therapeutic value for group 2 
LN dissection.
Conclusion    Because metastasis to stations 13 and 14v 
occurs frequently in patients with T3/T4 gastric cancer 
located in the lower third of the stomach who also have 
metastasis to group 2 LNs, stations 13 and 14v should be 
dissected in these patients.
Key words    gastric cancer; lymph node dissection; 
prognosis
Gastric cancer is one of the most common cancers in 
Asia, and its mortality still ranks second among all 
cancer deaths worldwide.1 In Japan, gastrectomy with 
D2 lymph node (LN) dissection is performed safely and 
is widely accepted as a standard treatment for locally 
advanced gastric cancer.2, 3 According to the Gastric 
Cancer Treatment Guidelines, the extent of dissection 
required for D2 LN dissection varies according to the 
type of gastrectomy.4 Because distal gastrectomy is usu-
ally performed for lower-third gastric cancer, required 
LNs stations are 1, 3a, 3b, 4sb, 4d, 5, 6, 7, 8a, 9, 11p, and 
12a to achieve D2 LN dissection. However, the suitable 
extent of LN dissection is still controversial. The LNs 
along the superior mesenteric vein are referred to as 
station 14v according to the 2nd English edition of the 
Japanese Classification of Gastric Carcinoma (JCGC).5 
These nodes receive the majority of lymphatic drainage 
from the lower third of the stomach and used to be con-
ventionally included in the N2 group according to the 
previous Japanese classification.5 In the past, the need 
for 14v dissection has been assessed based on anatom-
ical location in the lymphatic drainage pathway and on 
the frequency of 14v metastasis as reported in several 
Japanese studies.6, 7 However, some papers have demon-
strated that 14v dissection does not contribute to the 
prognosis of gastric cancer patients.8 Therefore, the lat-
est version of the Gastric Cancer Treatment Guidelines 
excludes station 14v from the nodes required for D2 LN 
dissection in gastric cancer located in the lower third of 
the stomach.4 
 The LNs on the posterior surface of the pancreatic 
head are referred to as station 13 according to the second 
English edition of the Japanese Classification of Gastric 
Carcinoma.5 Because of its anatomical location, gastric 
cancer in the lower third of the stomach preferentially 
metastasizes to station 13 LNs.9, 10 However, the clinical 
significance and prognostic value of station 13 LN 
dissection remain controversial as well. The aim of this 
study was to evaluate therapeutic value of lymph node 
dissection of 13 and 14v LNs in gastric cancer located in 
the lower third of the stomach.
MATERIALS AND METHODS
Patients  
From 1980 to 2010, 2262 patients underwent gastrec-
tomy for gastric cancer at Tottori University Hospital, 
and 1210 patients were pathologically diagnosed with 
advanced gastric cancer. Among the patients with 
advanced gastric cancer, 355 patients had gastric cancer 
restricted to the lower third of the stomach and the 
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duodenum; these patients were recruited for analysis in 
this study. Patients with invasion involving the middle or 
upper third of the stomach were excluded from the pres-
ent study. All patients underwent open gastrectomy with 
regional LN dissection. The clinicopathological findings 
were determined according to the JCGC.5 Pathological 
diagnosis was made by single pathologist in our hospi-
tal. Clinicopathological features were retrospectively 
collected from the institute’s database. This study was 
approved by our institutional review board (1608A086), 
and informed consent requirement was waived for this 
retrospective study.
Therapeutic value of lymph node dissection 
The therapeutic value of LN dissection was evaluated 
by multiplying the frequency of metastasis to the station 
by the 5-year survival rate of patients with metastasis in 
that station as proposed by Sasako et al.9 
Statistical analysis  
Associations among factors were evaluated by the chi-
squared test. Five-year survival rates were calculated 
according to the Kaplan–Meier method. Survival data 
shown in the current study are for cancer-specific surviv-
al. To this end, patients who died from causes other than 
gastric cancer were considered lost to follow-up as of the 
time of death. The accepted level of significance was P 
< 0.05. Stat View software (Abacus Concepts; Berkeley, 
CA) was used for all statistical analyses.
RESULTS
Among 355 patients included in this study, station 13 
and 14v LN dissection was performed in 157 and 121 
patients, respectively. Table 1 shows the relationships 
among 13 and 14 lymph node dissection and clini-
copathological variables in gastric cancer patients. 
Patients who underwent station 13 LN dissection were 
significantly younger than those who did not undergo 
station 13 LN dissection (P < 0.0001). Tumor size was 
Table 1. Relationships among stations 13 and 14 lymph node dissection and clinicopathological variables in pa-
tients with gastric cancer
Variable 13 lymph node dissection 14v lymph node dissection
Performed
(n = 157)
Not performed
(n = 198) P value
Performed
(n = 121)
Not performed
(n = 234) P value
Age 60.6 ± 11.1 68.0 ± 11.2 < 0.0001 61.2 ± 12.0 66.6 ± 11.2 0.0002
Tumor size 7.1 ± 2.6 6.0 ± 2.7 0.0003 6.9 ± 2.6 6.3 ± 2.7 0.026
Sex 0.53 0.072
Male (n = 228) 98 (62.4%) 130 (65.7%) 70 (62.4%) 158 (65.7%)
Female (n = 127) 59 (37.6%) 68 (34.3%) 51 (37.6%) 76 (34.3%)
Histology a 0.17 0.47
Differentiated (n = 159) 64 (40.8%) 95 (48.0%) 51 (42.1%) 108 (46.2%)
Undifferentiated (n = 196) 93 (59.2%) 103 (52.0%) 70 (57.9%) 126 (53.8%)
Depth of invasion b 0.09 0.62
T2 / T3 (n = 158) 62 (39.5%) 96 (48.5%) 52 (43.0%) 107 (45.7%)
T4 (n = 197) 95 (60.5%) 102 (51.5%) 69 (57.0%) 127 (44.3%)
Lymph node metastasis 0.0023 0.0049
Absent (n = 104) 33 (21.0%) 71 (35.9%) 24 (19.8%) 80 (34.2%)
Present (n = 251) 124 (79.0%) 127 (64.1%) 97 (90.2%) 154 (65.8%)
Lymphatic invasion 0.35 0.29
Absent (n = 76) 30 (19.1%) 46 (23.2%) 22 (18.2%) 54 (23.1%)
Present (n = 279) 127 (80.9%) 152 (76.8%) 99 (81.8%) 180 (76.9%)
Venous invasion 0.99 0.021
Absent (n = 138) 61 (38.9%) 77 (38.9%) 37 (30.6%) 101 (43.2%)
Present (n = 217) 96 (61.1%) 121 (61.1%) 84 (69.4%) 133 (56.8%)
Stage of disease 0.013 0.14
I / II (n = 148) 54 (34.4%) 94 (47.5%) 44 (36.4%) 104 (44.4%)
III / IV (n = 207) 103 (65.6%) 104 (52.5%) 77 (63.6%) 130 (55.6%)
All results are expressed as the mean ± SD.
a Differentiated, papillary, or tubular adenocarcinoma; undifferentiated, poorly differentiated, mucinous adenocarcinoma, and signet-ring 
cell carcinoma.
b Depth of invasion: T2, tumor invasion of the muscularis propria; T3, tumor invasion of the subserosa; T4, tumor penetration of the serosa 
or tumor invasion of adjacent organs
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Table 2. Relationship between the presence of stations 13 and 14 lymph node metastasis and clinicopathologi-
cal variables in patients with gastric cancer
Variable 13 lymph node metastasis 14v lymph node metastasis
n Absent (n = 141)  Present (n = 16) P value n Absent (n = 112)  Present (n = 9) P value
Age 60.3 ± 11.4 62.8 ± 8.1 0.59 61.3 ± 12.3 59.4 ± 5.3 0.32
Tumor size 7.0 ± 2.7 7.2 ± 1.7 0.51 6.9 ± 2.6 7.4 ± 1.8 0.35
Sex 0.11 1
Male 98 84 (59.6%) 13 (81.2%) 70 65 (62.4%) 5 (55.5%)
Female 59 57 (40.4%) 3 (18.8%) 51 47 (37.6%) 4 (44.5%)
Histology 0.066 0.077
Differentiated 74 61 (43.3%) 3 (18.8%) 51 50 (40.8%) 1 (11.1%)
Undifferentiated 83 80 (56.7%) 13 (81.2%) 70 62 (59.2%) 8 (88.9%)
Depth of invasion 0.1 0.09
T2 / T3 62 59 (41.8%) 3 (18.8%) 52 51 (45.5%) 1 (11.1%)
T4 95 82 (58.2%) 13 (81.2%) 69 61 (54.5%) 8 (88.9%)
Lymph node metastasis 0.025 0.2
Absent 33 33 (23.4%) 0 (0%) 88 24 (21.4%) 0 (0%)
Present 124 108 (76.6%) 16 (100%) 33 88 (78.6%) 9 (100%)
Lymphatic involvement 0.31 0.36
Absent 30 29 (20.6%) 1 (6.3%) 22 22 (19.6%) 0 (0%)
Present 127 112 (79.4%) 15 (93.7%) 99 90 (80.4%) 9 (100%)
Venous involvement 0.11 1
Absent 61 58 (41.1%) 3 (18.8%) 37 34 (30.4%) 3 (33.3%)
Present 96 83 (58.9%) 13 (81.2%) 84 78(69.6%) 6 (66.7%)
Stage of disease 0.013 0.026
I / II 54 54 (38.3%) 0 (0%) 44 44 (39.3%) 0 (0%)
III / IV 103 87 (61.7%) 16 (100%) 77 68 (60.7%) 9 (100%)
All results are expressed as the mean ± SD. See table 1 for the detail of histology and depth of invasion.
significantly larger in patients who underwent station 
13 LN dissection than in those who did not undergo 
station 13 LN dissection (P = 0.0003). Furthermore, the 
presence of LN metastasis was significantly more in 
patients who underwent station 13 LN dissection than in 
those who did not undergo station 13 LN dissection (P = 
0.0023). With regard to 14v LN dissection, patients who 
underwent station 14v LN dissection were significantly 
younger than those who did not undergo station 14v LN 
dissection (P = 0.0002). Tumor size was significantly 
larger in patients who underwent station 14v LN dissec-
tion than in those who did not undergo station 14v LN 
dissection (P = 0.026). Furthermore, the presence of LN 
metastasis and venous invasion was significantly more in 
patients who underwent station 14v LN dissection than 
in those who did not undergo station 14v LN dissection 
(P = 0.0049 for LN metastasis and P = 0.021 for venous 
invasion). We then determined the frequency of LN 
metastasis associated with gastric cancer located in the 
lower third of the stomach (Fig. 1). Station 1, 3, 4sb, 4d, 
5, 6, and 7 LNs are ones that are required to be dissected 
to achieve D1 LN dissection in gastric cancer located 
in the lower third of the stomach. Station 8a, 9, 11p, and 
12a LNs are ones that are required to be dissected to 
achieve D2 LN dissection in gastric cancer located in 
the lower third of the stomach. The frequency of LN 
metastasis was 10.2% and 7.4% for stations 13 and 14v, 
respectively, similar to that for the group 2 LNs, such as 
stations 9, 11p, and 12a. We then determined relation-
ship between the presence of 13 and 14 LN metastasis 
and clinicopathological variables in patients with gastric 
cancer (Table 2). Patients with LN metastasis and those 
with stage III / IV tumors had significantly more station 
13 LN metastasis than did those without LN metastasis 
(P = 0.025) and those with stage I / II tumors (P = 0.013). 
Patients with stage III / IV tumors had significantly more 
station 14v LN metastasis than did those with stage I / II 
tumors (P = 0.026). Figure 2 shows correlations between 
the depth of invasion and the frequency of metastasis 
to each LN station. Metastasis in station 1, 3, 4sb, 4d, 
5, 6, 7, 8a, 9, and 11p LNs was observed for T2 tumors. 
However, both station 13 and station 14v LN metastasis 
were observed for T3 and T4 tumors, but not for T2 
tumors. 
 We then determined the frequency of LN metas-
tasis to each station according to the status of station 
13 LN metastasis. Tumors with station 13 metastasis 
metastasized significantly more often to stations 6, 8a, 
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Fig. 1. The frequency of metastasis to each lymph node station in 
gastric cancer located in the lower third of the stomach.
Fig. 3. The frequency of metastasis to each lymph node station 
according to the presence of station 13 lymph node metastasis in 
gastric cancer located in the lower third of the stomach.
Fig. 5. The frequency of station 13 lymph node metastasis accord-
ing to the depth of invasion and the presence of metastasis to the 
group 2 lymph nodes in gastric cancer located in the lower third of 
the stomach. LN, lymph node. See Fig. 2 for the detail of depth of 
invasion.
Fig. 2. The frequency of metastasis to each lymph node station 
according to the depth of invasion in gastric cancer located in the 
lower third of the stomach. Depth of invasion: T2, tumor invasion 
of the muscularis propria; T3, tumor invasion of the subserosa; 
T4, tumor penetration of the serosa or tumor invasion of adjacent 
organs.
Fig. 4. The frequency of metastasis to each lymph node station 
according to the presence of station 14 lymph node metastasis in 
gastric cancer located in the lower third of the stomach.
Fig. 6. The frequency of station 14v lymph node metastasis 
according to the depth of invasion and the presence of metastasis 
to the group 2 lymph nodes in gastric cancer located in the lower 
third of the stomach. LN, lymph node. See Fig. 2 for the detail of 
depth of invasion.
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11, 12a, and 14v. Furthermore, this difference was more 
strikingly observed in the group 2 LNs, such as stations 
8a, 11p, and 12a, compared with the group 1 LN such 
as station 6 (Fig. 3). Tumors with station 14v metastasis 
metastasized signifi cantly more often to stations 3, 8a, 9, 
11p, 12a, and 13. This difference was also more striking-
ly observed in the group 2 LNs, such as stations 8a and 
12a, compared with the group 1 LN such as station 3 
(Fig. 4). The frequency of station 13 LN metastasis was 
26.8% for T3/T4 tumors with group 2 LN metastasis 
and 1.4% for all other tumors (Fig. 5). Furthermore, the 
frequency of station 14v LN metastasis was 22.2% for 
T3/T4 tumors with group 2 LN metastasis and 1.8% for 
all other tumors (Fig. 6). These results indicate that the 
presence of 13 and 14v LN metastasis could be predict-
ed based on the depth of invasion and the presence of 
metastasis to the group 2 LNs.
 The 5-year disease specifi c survival rates of patients 
with metastasis in each LN station were as follows: 
station 1, 21.9%; station 3, 28.2%; station 4sb, 33.3%; 
station 4d, 32.4%; station 5, 30.7%; station 6, 37.7%; sta-
tion 7, 30.6%; station 8a, 29.3%, station 9, 22.7%; station 
11p, 21%; station 12a, 10.5%; station 13, 18.8%; station 
14v, 12.5%. Finally, we determined the therapeutic value 
of dissecting each LN station (Fig. 7). The therapeutic 
values for LN dissection of stations 13 and 14v were 1.9 
and 0.9, respectively, similar to the therapeutic value for 
group 2 LN dissection (i.e., stations 9, 11p, and 12a).
DISCUSSION
There is a general consensus regarding the role of 
regional LN dissection in gastric cancer surgery.11–13 
The optimal method to evaluate the therapeutic value 
of dissecting each LN station is randomized control 
trial (RCT) and some RCTs have been done in gastric 
cancer thus far. For instance, Songun et al. demonstrated 
that D2 lymphadenectomy is associated with lower 
locoregional recurrence and gastric-cancer-related death 
rates than D1 surgery, indicating that group 2 lymph 
node dissection was useful in improving the prognosis 
of gastric cancer patients.14 On the other hand, it is now 
accepted that prophylactic para-aortic LN dissection 
confers no survival advantage,15, 16 However, the optimal 
extent of LN dissection is still controversial since it is 
diffi cult to conduct RCT. Therefore, it is indispensable to 
develop other methods to evaluate the therapeutic value 
of each LN dissection. In this regard, Sasako et al. de-
veloped new method, known as therapeutic value index, 
to evaluate the therapeutic value of each LN dissection 
for gastric cancer. This index includes the prognosis of 
the patients with metastasis to the station, as well as the 
metastatic incidence and used in many studies of gastric 
cancer to evaluate the theoretical therapeutic impact of 
dissecting each LN station.10, 17 The high therapeutic val-
ue index of the LN station indicates that the dissection 
of that LN station is useful in improving the prognosis 
of gastric cancer patients.
 The therapeutic value of station 13 LN dissection 
remains controversial. Tokunaga et al. showed that the 
frequency of station 13 LN metastasis in patients with 
advanced gastric cancer restricted to the lower third of 
the stomach and the duodenum was 23.9% in cases with 
duodenal invasion and 7% in cases without duodenal 
invasion; this difference was statistically significant.10 
In our study, the frequency of station 13 LN metastasis 
in patients with advanced gastric cancer restricted to 
the lower third of the stomach and the duodenum was 
16.7% in cases with duodenal invasion and 9.7% in cases 
without duodenal invasion, which is almost identical to 
the previous report, indicating that metastasis to the 13 
and 14v LNs occurs frequently in patients with gastric 
cancer located in the lower third of the stomach. Sasako 
et al. reported a 5-year survival rate of 0% for cases of 
lower-third advanced gastric cancer with station 13 LN 
metastasis. Therefore, these authors discounted any 
therapeutic value in station 13 LN dissection.9 In con-
trast, Tokunaga et al. reported a 5-year survival rate of 
17.5% in advanced gastric cancer patients with duodenal 
invasion and station 13 LN metastasis; the frequency 
of metastasis to these LNs was 23.9%. As a result, the 
therapeutic index for station 13 LN dissection in these 
advanced gastric cancer patients with duodenal invasion 
was 4.19, equivalent to that for most second-tier LNs. 
Therefore, these authors concluded that station 13 LNs 
should be dissected in patients with advanced gastric 
cancer with macroscopic duodenal invasion.10 Our re-
sults demonstrated that a 5-year survival rate was 18.8% 
in advanced gastric cancer patients with station 13 LN 
Saito et al. Figure 7
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Fig. 7. The therapeutic value of dissection at each lymph node 
station in gastric cancer located in the lower third of the stomach.
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metastasis in this study. Furthermore, therapeutic index 
for station 13 LN dissection was almost equivalent to 
that for group 2 LNs such as stations 9, 11p, and 12a, in-
dicating that station 13 LN dissection might be useful in 
improving the prognosis of patients with gastric cancer 
located in the lower third of the stomach. On the other 
hand, it remains unclear whether there is difference in 
therapeutic index for station 13 LN dissection according 
to the presence of duodenal invasion in the current study 
because of the small number of patients with duodenal 
invasion in the current study. Further investigations are 
urgently required in this regard.
 With regard to the station 14v nodes, An et al. 
reported overall 3- and 5-year survival rates of 26% and 
10%, respectively, in patients with positive 14v nodes 
who underwent R0 resections. Because the prognosis for 
patients with positive 14v nodes is poor, similar to that 
of patients with M1 disease, these authors concluded 
that exclusion of the 14v LNs from regional lymph node 
dissection should be considered.8 In the current study, a 
similar 5-year survival rate of 12.5% was found in pa-
tients with positive 14v nodes. The therapeutic index for 
14v LN dissection identified in our study was equivalent 
to that for most second-tier LNs. Therefore, 14v LN 
dissection has therapeutic value if R0 resection can be 
achieved.
 Dissection of the station 13 and 14v LNs is techni-
cally demanding. Therefore, it is important to select pa-
tients who have a possibility of metastasis to these LNs. 
In this regard, Masuda et al. reported that the station 
6 status was a useful predictive factor for 14v-negative 
status.18 Tumors with station 13 metastasis metastasized 
significantly more often to stations 6, 8a, 11, and 12a in 
this study. Tumors with station 14v metastasis metasta-
sized significantly more often to stations 3, 8a, 9, 11p, 
and 12a. These results indicate the possibility that there 
are lymphatic flows from these LNs to 13 and 14v LNs. 
In the current study, furthermore, we have demonstrated 
that patients who have T3/T4 tumors with metastasis 
to the group 2 LNs are likely to have metastasis to 
LN stations 13 and 14v. Therefore, stations 13 and 14v 
should be dissected in patients with T3/T4 gastric cancer 
located in the lower third of the stomach who also have 
possible metastasis to the group 2 LNs. 
 The present study has a few limitations. First, some 
bias was present because the study was retrospective. 
Particularly, the number of patients who underwent the 
dissection of LN stations 13 and 14v is 157 (44.2%) and 
121 (34.1%), respectively, and is smaller than that of 
patients who underwent the dissection of group 1 and 2 
LNs. Second, the number of patients included in the cur-
rent study was small; therefore, a large-scale, prospec-
tive randomized controlled trial is needed to confirm the 
results.
 In conclusion, the dissection of LN stations 13 and 
14v might be beneficial for survival in patients with 
gastric cancer located in the lower third of the stomach. 
Because metastasis to the 13 and 14v LNs occurs fre-
quently in patients with T3/T4 gastric cancer located in 
the lower third of the stomach who also have group 2 
LN metastasis, stations 13 and 14v should be dissected 
in these patients.
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